Literature DB >> 21622252

MicroRNA-122: a therapeutic target for hepatitis C virus (HCV) infection.

Giuseppe Nunnari1, Matthias J Schnell.   

Abstract

Hepatitis C virus infection is the main cause of liver disease worldwide, often leading to chronic hepatitis. Recent studies have demonstrated that miRNA-122, a liver-specific miRNA, is required for HCV replication in hepatocytes by its binding to the 5' UTR of HCV. Down-regulation of miRNA-122 in vitro and in vivo has led to significant inhibition of viral replication. In the present article, we report the major recent findings on the potential therapeutic role of anti-miRNA-122 molecules.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21622252     DOI： 10.2741/207

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN： 1945-0516


  10 in total

1.  miR-122 regulates hepatic lipid metabolism and tumor suppression.

Authors:  Jessica Wen; Joshua R Friedman
Journal:  J Clin Invest       Date:  2012-07-23       Impact factor: 14.808

2.  Preclinical evaluation of an anti-HCV miRNA cluster for treatment of HCV infection.

Authors:  Xiao Yang; Katherine Marcucci; Xavier Anguela; Linda B Couto
Journal:  Mol Ther       Date:  2013-01-08       Impact factor: 11.454

3.  MicroRNAs in ischemia-reperfusion injury.

Authors:  Jakob Bw Weiss; Steffen U Eisenhardt; G Björn Stark; Christoph Bode; Martin Moser; Sebastian Grundmann
Journal:  Am J Cardiovasc Dis       Date:  2012-07-25

4.  Curcumin protects against concanavalin A-induced hepatitis in mice through inhibiting the cytoplasmic translocation and expression of high mobility group box 1.

Authors:  Chuan-tao Tu; Qun-yan Yao; Bei-li Xu; Shun-cai Zhang
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

Review 5.  STAT3 regulation of and by microRNAs in development and disease.

Authors:  Arash Haghikia; Melanie Hoch; Britta Stapel; Denise Hilfiker-Kleiner
Journal:  JAKSTAT       Date:  2012-07-01

6.  Protective effects of N-acetylcysteine in concanavalin A-induced hepatitis in mice.

Authors:  Chengfen Wang; Yujing Xia; Yuanyuan Zheng; Weiqi Dai; Fan Wang; Kan Chen; Jingjing Li; Sainan Li; Rong Zhu; Jing Yang; Qin Yin; Huawei Zhang; Junshan Wang; Jie Lu; Yingqun Zhou; Chuanyong Guo
Journal:  Mediators Inflamm       Date:  2015-03-02       Impact factor: 4.711

7.  Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature.

Authors:  Bruno Cacopardo; Francesco Benanti; Marilia Rita Pinzone; Giuseppe Nunnari
Journal:  BMC Res Notes       Date:  2013-10-30

8.  Mechanistic Roles of Noncoding RNAs in Lung Cancer Biology and Their Clinical Implications.

Authors:  Katey S S Enfield; Larissa A Pikor; Victor D Martinez; Wan L Lam
Journal:  Genet Res Int       Date:  2012-07-18

9.  MicroRNAs in Cerebral Ischemia.

Authors:  Yang Wang; Yongting Wang; Guo-Yuan Yang
Journal:  Stroke Res Treat       Date:  2013-03-06

Review 10.  Cyclophilin A as a New Therapeutic Target for Hepatitis C Virus-induced Hepatocellular Carcinoma.

Authors:  Jinhwa Lee
Journal:  Korean J Physiol Pharmacol       Date:  2013-10-17       Impact factor: 2.016
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.